查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1967928

全球毒理學檢測外包市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Toxicity Testing Outsourcing Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 135 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計毒性測試外包市場將從 2025 年的 45.6 億美元成長到 2034 年的 107.7 億美元，2026 年至 2034 年的複合年成長率為 10.03%。

隨著製藥、生物技術、農業化學品和特種化學品公司越來越依賴受託研究機構(CRO) 進行符合良好實驗室規範 (GLP) 的非臨床安全性測試，毒性測試外包市場正經歷顯著成長。生物製劑、細胞和基因療法以及新型小分子化合物的開發平臺不斷擴展，推動了對涵蓋體外、體內和計算方法的綜合毒理學檢測服務的需求。 CRO 在設備容量和方法多樣性方面的投入，使申辦方能夠有效地降低早期研發階段的風險。

關鍵成長要素包括製藥和生物技術產業研發投入的增加、人體臨床試驗監管安全要求的日益嚴格，以及新型治療方法的複雜性不斷提高，需要專門的檢測技術。高通量體外檢測、晶片器官模型和預測性計算毒理學的進步，透過縮短試驗週期和提高轉化預測的準確性，提升了合約研究組織（CRO）的提案。儘管成本壓力和對可預測試驗進度的需求推動了外包，但CRO之間的策略聯盟和併購正在擴大其全球服務覆蓋範圍。

前景依然強勁。隨著新型療法和生物製藥鼓勵採用減少動物使用的替代方法，市場需求將會增加。投資於人工智慧驅動的風險評估、轉換模型和監管諮詢的合約研究組織（CRO）將脫穎而出。區域產能擴張，尤其是在亞洲，將帶來成本和進度優勢，而從藥物發現到首次人體臨床試驗的一體化服務將吸引尋求單一合作夥伴解決方案的申辦者。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球毒理學檢測外包市場：依方法分類

  • 市場分析、洞察與預測
  • In Vitro
  • In Vivo

第5章：全球毒理學檢測外包市場：依GLP類型分類

  • 市場分析、洞察與預測
  • GLP
  • 非GLP規範

第6章：全球毒理學檢測外包市場：依最終用途分類

  • 市場分析、洞察與預測
  • 製藥和生物製藥公司
  • 學術研究機構
  • 其他

第7章 全球毒理學檢測外包市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 亞太其他地區
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Eurofins Scientific
    • SGS SA
    • Charles River Laboratories
    • Thermo Fisher Scientific Inc
    • Intertek Group Plc
    • Catalent Inc
    • ICON Plc
    • Medpace
    • Wuxi AppTec
    • Labcorp Drug Development
簡介目錄
Product Code: VMR11219466

The Toxicity Testing Outsourcing Market size is expected to reach USD 10.77 Billion in 2034 from USD 4.56 Billion (2025) growing at a CAGR of 10.03% during 2026-2034.

The toxicity testing outsourcing market has grown substantially as pharmaceutical, biotech, agrochemical, and specialty chemical companies increasingly rely on contract research organizations (CROs) for GLP-compliant preclinical safety studies. Rising R&D pipelines-driven by biologics, cell and gene therapies, and novel small molecules-have expanded demand for comprehensive toxicology packages spanning in vitro, in vivo, and computational methods. CRO investments in capacity and assay diversity enabled sponsors to de-risk early stage development efficiently.

Key growth drivers include escalating R&D spend across pharma and biotech, stringent regulatory safety requirements for human trials, and the complexity of new therapeutic modalities that require specialized testing expertise. Advances in high-throughput in vitro assays, organ-on-chip models, and predictive computational toxicology increase CRO value propositions by shortening timelines and improving translational predictivity. Cost pressures and the need for predictable study timelines encourage outsourcing, while strategic partnerships and M&A among CROs expand global service footprints.

Future prospects are strong: demand will rise as novel therapeutics and biologics require deeper safety characterization, and as regulators incentivize alternative methods that reduce animal use. CROs that invest in AI-driven risk assessment, translational models, and regulatory consulting will differentiate. Regional capacity expansion-notably in Asia-offers cost and timeline advantages, and integrated service offerings (discovery-to-first-in-human) will attract sponsors seeking single-partner solutions.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Method

  • In Vitro
  • In Vivo

By GLP Type

  • GLP
  • Non GLP

By End-Use

  • Pharmaceutical And Biopharmaceutical Companies
  • Academic And Research Institutes
  • Others

COMPANIES PROFILED

  • Eurofins Scientific, SGS SA, Charles River Laboratories, Thermo Fisher Scientific Inc, Intertek Group plc, Catalent Inc, ICON plc, Medpace, Wuxi AppTec, Labcorp Drug Development
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL TOXICITY TESTING OUTSOURCING MARKET: BY METHOD 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Method
  • 4.2. In Vitro Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. In Vivo Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL TOXICITY TESTING OUTSOURCING MARKET: BY GLP TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Glp Type
  • 5.2. GLP Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Non GLP Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL TOXICITY TESTING OUTSOURCING MARKET: BY END-USE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End-use
  • 6.2. Pharmaceutical And Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Academic And Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL TOXICITY TESTING OUTSOURCING MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Method
    • 7.2.2 By Glp Type
    • 7.2.3 By End-use
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Method
    • 7.3.2 By Glp Type
    • 7.3.3 By End-use
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Method
    • 7.4.2 By Glp Type
    • 7.4.3 By End-use
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Method
    • 7.5.2 By Glp Type
    • 7.5.3 By End-use
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Method
    • 7.6.2 By Glp Type
    • 7.6.3 By End-use
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL TOXICITY TESTING OUTSOURCING INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Eurofins Scientific
    • 9.2.2 SGS SA
    • 9.2.3 Charles River Laboratories
    • 9.2.4 Thermo Fisher Scientific Inc
    • 9.2.5 Intertek Group Plc
    • 9.2.6 Catalent Inc
    • 9.2.7 ICON Plc
    • 9.2.8 Medpace
    • 9.2.9 Wuxi AppTec
    • 9.2.10 Labcorp Drug Development